IMUX

Immunic Inc

Immunic to Participate in Investor Conferences in March Immunic to Participate in Investor Conferences in March PR Newswire NEW YORK, March 3, 2026 NEW YORK, March 3, 2026 /PRNewswire/ -- Immunic...

HC Wainwright dropped their target price on shares of Immunic from $8.00 to $5.00 and set a "buy" rating on the stock in a report on Monday...

Immunic (NASDAQ:IMUX - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of...

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update PR Newswire NEW YORK, Feb. 26...

Shares of Immunic, Inc. (NASDAQ:IMUX - Get Free Report) have been given a consensus rating of "Buy" by the nine analysts that are covering the stock, Marketbeat Ratings reports. One research analyst...

Immunic (NASDAQ:IMUX) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

Immunic Announces Closing of Oversubscribed Private Placement Financing Immunic Announces Closing of Oversubscribed Private Placement Financing PR Newswire NEW YORK, Feb. 17, 2026 Upfront Proceeds of...

In biotechnology, few milestones carry more weight than securing the capital required to cross the finish line. As clinical-stage companies approach pivotal trials and potential commercialization, access to substantial funding can dramatically reshape both timelines and investor perception.Shares of Immunic, Inc. (Nasdaq: IMUX) are climbing Friday morning after the late-stage biotechnology company announced an oversubscribed private placement of up to $400 million, priced at the market under Nasdaq rules. The financing includes $200 million in upfront gross proceeds, with the potential for ...

In biotechnology, few milestones carry more weight than securing the capital required to cross the finish line. As clinical-stage companies approach pivotal trials and potential commercialization, access to substantial funding can dramatically reshape both timelines and investor perception.Shares of Immunic, Inc. (Nasdaq: IMUX) are climbing Friday morning after the late-stage biotechnology company announced an oversubscribed private placement of up to $400 million, priced at the market under Nasdaq rules. The financing includes $200 million in upfront gross proceeds, with the potential for ...